Cancer clinical trials in the region Grand Est

292 currently recruiting clinical trials
Region Grand Est
Phase 2 Head and neck cancer #NCT06640725 #2023-510559-41-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
7 recruiting sites
Groupe Oncologie Radiothérapie Tête et Cou (GORTEC)
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Skin cancer #NCT02029001 #2012-004510-34
Cohorte Durvalumab + Tremelimumab
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Bispecific T-cell engager antibodies
7 recruiting sites
Centre Léon Bérard
Phase 2 Penile cancer and germ cell tumors #NCT05529251 #2024-514636-25-00
Required histologic types
Germ cell tumor
Required histologic sub types
Pure seminoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required primary sites
Testis
Required IGCCCG prognostic scores
Good prognosis
Excluded previous treatments at localized stage
Surgery Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
12 recruiting sites
Centre Léon Bérard
Phase 2 Lymphoma Brain tumors / Central nervous system tumors #NCT07015242 #2025-521144-38-00
Required histologic types
B cell lymphoma Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma Primary CNS lymphoma
Required central nervous system lesions
Actives
Required number of previous lines of therapy
None
Excluded previous treatments
Car-T Allogeneic stem cell transplant
13 recruiting sites
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Endometrial cancer Sarcoma and GIST #NCT03624244
Required histologic types
Soft tissue sarcoma
Required histologic sub types
Other
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
18 recruiting sites
Centre Léon Bérard
Phase 2 Pancreas cancer #NCT07483983 #2025-522533-54-00
Cohorte pancréas
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12D
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Stomach and esophageal cancer #NCT06059495
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Radiotherapy
11 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2 Lung cancer #NCT06656598 #2024-517316-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR ROS-1
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
25 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 2 Lung cancer #NCT06840834 #2024-519052-82-00
Required histologic types
Mesothelium
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
17 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 2 Lymphoma #NCT06558604 #2023-506706-40-00
Cohorte C
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II) Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)